Why underpowered studies are more dangerous than you think
In epidemiology, statistical power determines whether a study can accurately detect an effect of a...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our...
Does your data link?
How clinical data linkage closes evidence gaps in real-world data Clinical data linkage helps...
Why 'good enough' data is risky
Real World Data (RWD) is increasingly being incorporated into healthcare and life science research...
Can you trust AI for RWE? HealthVerity eXOs validation study says yes
Artificial intelligence is moving quickly into healthcare research, but one question still comes...
The role of real-world data in advancement of Alzheimer’s treatments
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...
Inside taXonomy, a next-gen closed claims solution for real-world evidence generation
Healthcare claims data are one of the most powerful sources of data in generating real-world...
Rethinking healthcare audience targeting for data-driven precision
Why healthcare marketers need more transparency in audience targeting Healthcare marketers are...
What The Pitt gets right about AI and clinical notes
In Season 2 of The Pitt, Dr. Santos accepts an AI-drafted clinical note and moves on. It’s one of...
Why diagnosis codes alone fall short for long COVID surveillance
When our client, a global pharmaceutical company, set out to better understand long COVID pathways,...